Clinical trial
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With…
NCT02316106 · Janssen Research & Development, LLC, Industry · Completed
Key facts
| NCT number | NCT02316106 |
|---|---|
| Title | A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma |
| Official title | A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma |
| Lead sponsor | Janssen Research & Development, LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | daratumumab |
| Enrollment | 123 |
| Start date | May 20, 2015 |
| Primary completion | Jun 2, 2023 |
| Completion | Jun 3, 2024 |
| First posted | Dec 12, 2014 |
| Last update posted | Apr 27, 2025 |
| Countries | Australia, Canada, Czechia, France, Germany, Israel, Netherlands, Russia, Turkey (Türkiye), United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: